In other words, MS patients with poor response to IFN-β seem to exhibit an already fully activated type I IFN signaling pathway that is refractory to the therapeutic administration of exogenous IFN-β since it cannot be activated further. Here, IFNB1 is linked to myeloid sarcoma.